New 6-Month shot shows promise for prostate cancer control

NCT ID NCT05590793

Completed Disease control Sponsor: Ipsen Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested a single injection of triptorelin pamoate that lasts 6 months in 195 Chinese men with advanced or metastatic prostate cancer. The goal was to lower testosterone to castrate levels, which helps slow cancer growth. Results showed the injection effectively reduced and maintained low testosterone levels, with manageable side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: triptorelin pamoate (a hormone-blocking drug)
What this could lead to: If successful, this could offer a convenient 6-month injection option for managing advanced prostate cancer in Chinese patients.
What could go wrong: This is a single-arm, open-label study without a comparison group, so results may not be definitive. Side effects from hormone suppression are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED PROSTATE CANCER LOCALLY ADVANCED PROSTATE CANCER METASTATIC PROSTATE CANCER

Contacts and locations

Locations

Affiliated Hospital of Hebei University

Baoding, China
Beijing Hospital

Beijing, China
Chongqing University Cancer Hospital

Chongqing, China
Deyang People's Hospital

Deyang, China
Fudan University Shang Hai Cancer Center

Shanghai, China
Guizhou Provincial People's Hospital

Guiyang, China
Henan Cancer Hospital

Zhengzhou, China
Hunan Cancer Hospital

Changsha, China
Liaoning Cancer Hospital & Institute

Shenyang, China
Nanjing Drum Tower Hospital

Nanjing, China
Ningbo First Hospital

Ningbo, China
Northern Jiangsu People's Hospital

Yangzhou, China
Peking University First Hospital

Beijing, China
Peking University People's Hospital

Beijing, China
Peking University Shenzhen Hospital

Shenzhen, China
Qilu Hospital of Shandong University

Jinan, China
Shandong Provincial Hospital

Jinan, China
Shanghai Fifth People's Hospital

Shanghai, China
Shanghai Tongji Hospital

Shanghai, China
Subei People's Hospital

Yangzhou, China
Suining Central Hospital

Suining, China
Sun Yat-Sen University Cancer Center

Guangzhou, China
The Affiliated Hospital of Guizhou Medical University

Guiyang, China
The First Affiliated Hospital of Chongqing Medical University

Chongqing, China
The First Affiliated Hospital of Wannan Medical College

Wuhu, China
The First Affiliated Hospital of Wenzhou Medical University

Wenzhou, China
The First Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, China
The First Hospital of China Medical University

Shenyang, China
The Second Affiliated Hospital of Soochow University

Suzhou, China
The Second Affiliated Hospital of Wannan Medical College

Wuhu, China
Tianjin Cancer Hospital

Tianjin, China
West China Hospital of Sichuan University

Chengdu, China
Wuxi People's Hospital

Wuxi, China
Yantai Yuhuangding Hospital

Yantai, China
Zhongda Hospital Southeast University

Nanjing, China
Zigong First People's Hospital

Zigong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.